154 related articles for article (PubMed ID: 24338530)
1. In silico study on indole derivatives as anti HIV-1 agents: a combined docking, molecular dynamics and 3D-QSAR study.
Balupuri A; Gadhe CG; Balasubramanian PK; Kothandan G; Cho SJ
Arch Pharm Res; 2014 Aug; 37(8):1001-15. PubMed ID: 24338530
[TBL] [Abstract][Full Text] [Related]
2. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
3. Is the conformational flexibility of piperazine derivatives important to inhibit HIV-1 replication?
Teixeira C; Serradji N; Amroune S; Storck K; Rogez-Kreuz C; Clayette P; Barbault F; Maurel F
J Mol Graph Model; 2013 Jul; 44():91-103. PubMed ID: 23748247
[TBL] [Abstract][Full Text] [Related]
4. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking guided structure based design of symmetrical N,N'-disubstituted urea/thiourea as HIV-1 gp120-CD4 binding inhibitors.
Sivan SK; Vangala R; Manga V
Bioorg Med Chem; 2013 Aug; 21(15):4591-9. PubMed ID: 23777826
[TBL] [Abstract][Full Text] [Related]
6. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives.
Wang T; Kadow JF; Zhang Z; Yin Z; Gao Q; Wu D; Parker DD; Yang Z; Zadjura L; Robinson BA; Gong YF; Spicer TP; Blair WS; Shi PY; Yamanaka G; Lin PF; Meanwell NA
Bioorg Med Chem Lett; 2009 Sep; 19(17):5140-5. PubMed ID: 19664921
[TBL] [Abstract][Full Text] [Related]
8. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
9. Binding site exploration of CCR5 using in silico methodologies: a 3D-QSAR approach.
Gadhe CG; Kothandan G; Cho SJ
Arch Pharm Res; 2013 Jan; 36(1):6-31. PubMed ID: 23325486
[TBL] [Abstract][Full Text] [Related]
10. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
11. Rational Design of Colchicine Derivatives as anti-HIV Agents via QSAR and Molecular Docking.
Worachartcheewan A; Songtawee N; Siriwong S; Prachayasittikul S; Nantasenamat C; Prachayasittikul V
Med Chem; 2019; 15(4):328-340. PubMed ID: 30251609
[TBL] [Abstract][Full Text] [Related]
12. Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120.
Vangala R; Sivan SK; Peddi SR; Manga V
J Comput Aided Mol Des; 2020 Jan; 34(1):39-54. PubMed ID: 31792886
[TBL] [Abstract][Full Text] [Related]
13. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M
ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750
[TBL] [Abstract][Full Text] [Related]
14. Linear and non-linear quantitative structure-activity relationship models on indole substitution patterns as inhibitors of HIV-1 attachment.
Nirouei M; Ghasemi G; Abdolmaleki P; Tavakoli A; Shariati S
Indian J Biochem Biophys; 2012 Jun; 49(3):202-10. PubMed ID: 22803336
[TBL] [Abstract][Full Text] [Related]
15. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential HIV-1 integrase strand transfer inhibitors: in silico virtual screening and QM/MM docking studies.
Reddy KK; Singh SK; Tripathi SK; Selvaraj C
SAR QSAR Environ Res; 2013; 24(7):581-95. PubMed ID: 23521430
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
[TBL] [Abstract][Full Text] [Related]
18. CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.
Narumi T; Arai H; Yoshimura K; Harada S; Hirota Y; Ohashi N; Hashimoto C; Nomura W; Matsushita S; Tamamura H
Bioorg Med Chem; 2013 May; 21(9):2518-26. PubMed ID: 23535561
[TBL] [Abstract][Full Text] [Related]
19. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
AbdulHameed MD; Hamza A; Liu J; Zhan CG
J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
[TBL] [Abstract][Full Text] [Related]
20. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
